Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6373.0000 -89.50 (-1.38%)
NSE Nov 21, 2025 15:48 PM
Volume: 130.8K
 

logo
Divi's Laboratories Ltd.
20 Apr 2020, 12:00AM
6373.00
-1.38%
ICICI Securities Limited
On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....
Number of FII/FPI investors decreased from 990 to 897 in Sep 2025 qtr
More from Divi's Laboratories Ltd.
Recommended